Topline Findings
- AbbVie Investment: AbbVie commits $195 million to expand active pharmaceutical ingredient manufacturing at its North Chicago facility, supporting next-generation neuroscience, immunology, and oncology medicines.
- US Manufacturing Boost: Construction of the new facility will begin in 2025, with operations expected by 2027, adding to AbbVie’s 11 US sites and thousands of supplier roles nationwide.
- Industry Response to Tariffs: Major pharma companies, including Merck, Roche, Novartis, and Johnson & Johnson, announced significant US investments this year, highlighting a broader trend in domestic pharmaceutical manufacturing growth.
AbbVie has announced a $195 million investment to expand active pharmaceutical ingredient (API) manufacturing at its North Chicago, Ill facility. This initiative is part of the company's broader commitment to invest over $10 billion in US innovation and manufacturing capabilities. The expansion aims to enhance AbbVie's domestic chemical synthesis capacity to support current and next-generation neuroscience, immunology, and oncology medicines.1
AbbVie’s Expansion is Latest in US Biopharmaceutical Manufacturing Growth
"Over the next decade, AbbVie will expand production of API, drug product, peptides and medical devices in the US to support future medical breakthroughs," said Robert A. Michael, chairman, CEO, AbbVie, in a press release. "This is an important step to maintain US leadership in pharmaceutical innovation and deliver next-generation medicines that make a remarkable impact on patients' lives."
Tariffs and Industry Response
Construction of the new facility is expected to begin later this year, with operations slated to commence by 2027. AbbVie stated that the facility will augment its manufacturing network in the United States, which currently comprises 11 sites employing more than 6,000 people. The site is anticipated to support additional roles through suppliers across the country.1
- The announcement coincides with President Trump’s move to impose global, reciprocal tariffs on the pharmaceutical industry, a policy shift with potential implications for manufacturing and supply chains.
- In April, the President expressed his belief that these tariffs would incentivize pharmaceutical companies to relocate to the United States.2
- In a recent interview with CNBC, Trump stated that the tariffs could reach up to 250%.
- Initially, a smaller tariff is planned, with the possibility of increasing over the next year to 18 months, aiming to have drugs manufactured in the United States and sold to Americans at prices aligned with his Most-Favored-Nation policy.3
“We’re going to tariff our pharmaceuticals, and once we do that, they are going to come rushing back into our country, because we’re the big market," said Trump, at an April dinner event on Capitol Hill with House Republicans. “The advantage we have over everybody is that we’re the big market. So, we’re going to be announcing very shortly a major tariff on pharmaceuticals, and when they hear that, they will leave China, they will leave other places, because most of their product is sold here and they’re going to be opening up their plants all over our country.”2
